Organics Announces Proposed Underwritten Public Offering
November 19 2020 - 4:22PM
Business Wire
Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the
“Company”) a company focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic, today
announced that it has commenced a proposed underwritten public
offering of common stock of the Company. In addition, the Company
expects to grant the underwriter of the offering, a 45-day option
to purchase additional shares of common stock at the public
offering price, less underwriting discounts and commissions. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
A.G.P./Alliance Global Partners is acting as sole book-running
manager for the offering.
The Company intends to use the net proceeds of the offering
primarily to continue funding our pre-clinical development of our
SARS-CoV-2 vaccine, Terra CoV-2 and our lantibiotics program and
for general corporate purposes, including research and development
activities, capital expenditures and working capital.
The securities described above are being offered pursuant to a
shelf registration statement (File No. 333-235763), which was
declared effective by the United States Securities and Exchange
Commission (“SEC”) on January 13, 2020. A preliminary prospectus
supplement relating to the offering will be filed with the SEC.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained,
when available, at the SEC’s website at www.sec.gov. Electronic
copies of the preliminary prospectus supplement may be obtained,
when available, from A.G.P./Alliance Global Partners, 590 Madison
Avenue, 28th Floor, New York, NY 10022 or via telephone at
212-624-2060 or email: prospectus@allianceg.com.
Before you invest, you should read the preliminary prospectus
supplement and the accompanying prospectus in the registration
statement and other documents Oragenics has filed or will file with
the SEC for more complete information about Oragenics and the
offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the Company’s securities,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction.
About Oragenics, Inc.
Oragenics, Inc. is focused on the creation of the Terra CoV-2
vaccine candidate to combat the novel coronavirus pandemic and the
further development of effective treatments for novel antibiotics
against infectious disease. The Company is dedicated to the
development and commercialization of a vaccine candidate providing
specific immunity from novel coronavirus. The Terra CoV-2
immunization leverages coronavirus spike protein research conducted
by the National Institute of Health. In addition, Oragenics has an
exclusive worldwide channel collaboration with ILH Holdings, Inc.
(n/k/a Eleszto Genetika, Inc.), relating to the development of
novel lantibiotics.
Forward-Looking Statements
This press release contains “forward-looking statements” as
defined in the Private Securities Litigation Reform Act of 1995, as
amended, that involve significant risks and uncertainties about
Oragenics, including but not limited to statements with respect to
the completion, timing, size, and use of proceeds of the proposed
underwritten offering of common stock. Oragenics may use words such
as “expect,” “anticipate,” “project,” “intend,” “plan,” “aim,”
“believe,” “seek,” “estimate,” “can,” “focus,” “will,” and “may”
and similar expressions to identify such forward-looking
statements. Among the important factors that could cause actual
results to differ materially from those indicated by such
forward-looking statements are risks relating to, among other
things, whether or not Oragenics will be able to raise capital, the
final terms of the underwritten offering of common stock, market
and other conditions, the satisfaction of customary closing
conditions related to the underwritten offering of common stock,
Oragenics’ business and financial condition, and the impact of
general economic, industry or political conditions in the United
States or internationally. For additional disclosure regarding
these and other risks faced by Oragenics, see disclosures contained
in Oragenics’ public filings with the SEC, including the “Risk
Factors” in the Company’s Annual Report on Form 10-K, as updated by
our Form 8-K Report filed with the SEC on May 8, 2020, Quarterly
Reports on Form 10-Q, and prospectus for this offering. You should
consider these factors in evaluating the forward-looking statements
included in this press release and not place undue reliance on such
statements. The forward-looking statements are made as of the date
hereof, and Oragenics undertakes no obligation to update such
statements as a result of new information, except as required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201119006292/en/
Oragenics, Inc. Corporate: Michael Sullivan, 813-286-7900 Chief
Financial Officer msullivan@oragenics.com
or
Investors: John Marco Managing Director CORE IR
516-222-2560 johnm@coreir.com
Media: Jules Abraham CORE IR 917-885-7378
julesa@coreir.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024